Navigation Links
Alzheimer's Drug Discovery Foundation Awards Grant To CohBar to Develop A Novel Peptide Therapeutic For Alzheimer's Disease
Date:3/6/2013

NEW YORK, March 6, 2013 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded $205,260 in funding to CohBar Inc. to develop a novel mitochondrial peptide for the treatment of Alzheimer's disease (AD). The peptide has been shown to have neuro-protective effects against a variety of AD-related toxic insults, including amyloid-beta.

Based on a peptide called Humanin, CohBar's peptide acts by preventing neurons from dying, in part by improving mitochondrial function, reducing inflammation, increasing insulin sensitivity and decreasing oxidative stress.

"We are excited to support the development of CohBar's unique peptide, which affects several processes implicated in Alzheimer's disease progression," said Howard Fillit , MD, executive director and chief science officer for the ADDF. "We believe that a compound that targets all of these processes has the potential to be a promising new treatment for patients suffering with this disease."

The ADDF funds will support a year-long research program at CohBar that will include: a) evaluating the ability of the peptides to protect cell lines against a variety of Alzheimer disease related stresses, b) examining evidence that the peptides cross the blood brain barrier and c) an initial evaluation of the efficacy in mice. At the end of the program, researchers at CohBar plan to continue testing in more advanced animal research models of Alzheimer's disease.  

"We are pleased to be selected by the ADDF for this peer-reviewed grant, which recognizes the novelty of our scientific approach and the quality of our research capabilities," said Mark Rampy , PhD, chief executive officer of CohBar. "We look forward to working with the ADDF and advancing our research with novel Humanin analogs in the area of Alzheimer's disease."

John Amatuda, MD, co-founder of CohBar, notes there is great potential for evaluating Humanin analogs in Alzheimer's disease as well as other disease areas. "Our unique Humanin analogs hold significant potential as innovative medicines and this award provides critical funding to explore their promise in Alzheimer's disease," he says. "In addition, the association of insulin resistance and Alzheimer's disease, and the interesting finding that Humanin improves hepatic insulin resistance through a central mechanism, provide an intriguing and potentially important link between Humanin's positive effects on Alzheimer's disease and its effects to lower glucose in Type 2 diabetes."

About the Alzheimer's Drug Discovery Foundation (ADDF)
The mission of the Alzheimer's Drug Discovery Foundation (ADDF) is to accelerate the discovery of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. The ADDF has granted more than $60 million to fund almost 400 Alzheimer's drug discovery programs in academic centers and biotechnology companies in 18 countries. For more information, please visit www.AlzDiscovery.org

About CohBar Inc.
CohBar, Inc. is a privately held biotechnology company that leverages insights regarding mitochondrial communication and the critical role of mitochondrially-derived peptides (MDPs) in diseases of aging and human longevity. The company's innovative product pipeline and discovery capabilities are focused on MDPs as treatments for age-related diseases such as diabetes, cardiovascular disease, Alzheimer's disease and cancer as well as in the aging process itself. CohBar is developing a proprietary series of novel MDPs that have the potential to be new treatments for today's most pressing diseases. CohBar is headquartered in Los Angeles, California. For more information, please visit www.cohbar.com.


'/>"/>
SOURCE Alzheimer's Drug Discovery Foundation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. TeraDiscoveries to Use its Inverse Design Software Running on Windows Azure to Advance Its Computational Drug Discovery Process
2. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
3. Galenea to Receive $6 Million From The Stanley Medical Research Institute to Progress Pro-Cognitive Drug Discovery and Development Program
4. University Hospitals Case Medical Centers Harrington Discovery Institute Launches Grant Program to Accelerate Drug Discovery and Development
5. Dr. Paul Karila Appointed Head of Discovery Services at Cellectricon AB
6. Aethlon Medical (AEMD) Note: Cancer Research Discovery - Melanoma Exosomes Fuel Organ Metastasis
7. Drug Discovery Technologies Market Soars to $79 billion by 2017, Driven by Innovations in Pipeline and Tools Development
8. AMRI Further Expands Discovery Capabilities in India
9. Tetra Discovery Partners Receives Major NIH Award To Develop New Alzheimers Drug
10. Global Information, Inc. Announces New Market Forecasts For Drug Discovery Industry as it Emerges from Recession
11. Protein and Peptide-based Therapeutics - Trends in Drug Discovery and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... June 23, 2016 Bracket , a leading ... next generation clinical outcomes platform, Bracket eCOA (SM) 6.0, ... June 26 – 30, 2016 in Philadelphia ... Clinical Outcome Assessment product of its kind to fully integrate ... Bracket eCOA 6.0 is a flexible platform for electronic ...
(Date:6/23/2016)... Revolutionary technology includes multi-speaker listening ... industry leaders in advanced audiology and hearing aid technology, ... ™, the world,s first internet connected hearing aid that ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... ,world firsts,: , TwinLink™ - the first ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... ... skills and infrastructure. Most providers, however, are unsure how to move forward, given ... to define a path forward tailored to an organization’s specific needs. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, InhaleLabs.com (Inhale) offilially launched its ... by matching users with high quality water pipes within an ideal price range. The ... Inhale was founded by two brothers, Nick and Mike Hunter, who use medical cannabis ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Seema Daulat, a native Texan and University of ... location as of July 13, 2016. , Dr. Daulat earned her Doctorate of Medicine ... regularly volunteered at the Agape Clinic serving Dallas’ underprivileged community. , Following medical school, ...
(Date:6/23/2016)... Los Angeles, CA (PRWEB) , ... June 23, 2016 , ... ... being conducted that may expose a possible link between head and neck cancer in ... individuals participating in the study were evaluated based on whether they had gum disease, ...
(Date:6/23/2016)... ... June 23, 2016 , ... The Mechille Wilson Agency, a Texas-based insurance ... and the surrounding region, is initiating a charity drive to assist a student to ... for a scholarship fund that will be presented to the chosen student to help ...
Breaking Medicine News(10 mins):